Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | +0.88% | +1.33% | -59.43% |
Valuation
Fiscal Period: October | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 22.25 | 10.43 | 1.784 |
Enterprise Value (EV) 2 | 17.65 | 10.04 | -3.73 |
P/E ratio | -4.23 x | -1.09 x | -0.09 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -4,804,206 x | -1,180,698 x | 593,760 x |
EV / FCF | -11.1 x | -8.4 x | 6.13 x |
FCF Yield | -8.97% | -11.9% | 16.3% |
Price to Book | 4.63 x | -6.91 x | 2.26 x |
Nbr of stocks (in thousands) | 41.7 | 44 | 488 |
Reference price 3 | 533.6 | 237.0 | 3.657 |
Announcement Date | 22-02-28 | 23-01-31 | 24-01-29 |
Income Statement Evolution (Annual data)
Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA | - | - | - | -3.674 | -8.502 | -6.281 |
EBIT 1 | -0.2174 | -0.086 | -0.2086 | -3.866 | -8.533 | -6.303 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.1945 | -0.1053 | -0.2332 | -3.899 | -9.37 | -8.603 |
Net income 1 | -0.1945 | -0.1053 | -0.2332 | -3.899 | -9.411 | -8.621 |
Net margin | - | - | - | - | - | - |
EPS 2 | -18.05 | -8.537 | -12.86 | -126.2 | -217.2 | -42.58 |
Free Cash Flow 1 | -0.1781 | -0.0215 | -0.1716 | -1.583 | -1.195 | -0.6085 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 19-02-25 | 20-02-28 | 21-03-01 | 22-02-28 | 23-01-31 | 24-01-29 |
Balance Sheet Analysis
Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 0.07 | 0 | 0.33 | 4.6 | 0.39 | 5.51 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.18 | -0.02 | -0.17 | -1.58 | -1.2 | -0.61 |
ROE (net income / shareholders' equity) | -129% | -56.5% | -73.7% | -147% | -572% | 14,072% |
ROA (Net income/ Total Assets) | -72.3% | -25.3% | -37.7% | -85.2% | -170% | -116% |
Assets 1 | 0.269 | 0.4163 | 0.6181 | 4.577 | 5.547 | 7.418 |
Book Value Per Share 2 | 19.40 | 10.80 | 23.40 | 115.0 | -34.30 | 1.620 |
Cash Flow per Share 2 | 5.980 | 0.0600 | 15.40 | 110.0 | 4.000 | 8.940 |
Capex 1 | 0.13 | 0.01 | 0.01 | 0.03 | 0.01 | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 19-02-25 | 20-02-28 | 21-03-01 | 22-02-28 | 23-01-31 | 24-01-29 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-59.43% | 3.69M | |
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- CMND Stock
- Financials Clearmind Medicine Inc.